4.7 Article

Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B12

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 302, 期 19, 页码 2119-2126

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2009.1622

关键词

-

资金

  1. Advanced Research Program and Research Council of Norway
  2. Norwegian Foundation for Health and Rehabilitation
  3. Norwegian Council on Cardiovascular Disease
  4. Norwegian Heart and Lung Patient Organization
  5. Norwegian Red Cross
  6. Northern Norway Regional Health Authority
  7. Western Norway Regional Health Authority
  8. Norwegian Ministry of Health and Care Services
  9. University of Tromso, Tromso, Norway
  10. University of Bergen, Bergen, Norway
  11. Department of Heart Disease at Haukeland University Hospital, Bergen, Norway
  12. Foundation to Promote Research Into Functional Vitamin B12 Deficiency, Bergen, Norway

向作者/读者索取更多资源

Context Recently, concern has been raised about the safety of folic acid, particularly in relation to cancer risk. Objective To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials. Design, Setting, and Participants Combined analysis and extended follow-up of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Norwegian Vitamin Trial and Western Norway B Vitamin Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo between 1998 and 2005, and were followed up through December 31, 2007. Interventions Oral treatment with folic acid (0.8 mg/d) plus vitamin B-12 (0.4 mg/d) and vitamin B-6 (40 mg/d) (n=1708); folic acid (0.8 mg/d) plus vitamin B-12 (0.4 mg/d) (n=1703); vitamin B-6 alone (40 mg/d) (n=1705); or placebo (n=1721). Main Outcome Measures Cancer incidence, cancer mortality, and all-cause mortality. Results During study treatment, median serum folate concentration increased more than 6-fold among participants given folic acid. After a median 39 months of treatment and an additional 38 months of posttrial observational follow-up, 341 participants (10.0%) who received folic acid plus vitamin B-12 vs 288 participants (8.4%) who did not receive such treatment were diagnosed with cancer (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03-1.41; P=.02). A total of 136 (4.0%) who received folic acid plus vitamin B-12 vs 100 (2.9%) who did not receive such treatment died from cancer (HR, 1.38; 95% CI, 1.07-1.79; P=.01). A total of 548 patients (16.1%) who received folic acid plus vitamin B-12 vs 473 (13.8%) who did not receive such treatment died from any cause (HR, 1.18; 95% CI, 1.04-1.33; P=.01). Results were mainly driven by increased lung cancer incidence in participants who received folic acid plus vitamin B-12. Vitamin B-6 treatment was not associated with any significant effects. Conclusion Treatment with folic acid plus vitamin B-12 was associated with increased cancer outcomes and all-cause mortality in patients with ischemic heart disease in Norway, where there is no folic acid fortification of foods. Trial Registration clinicaltrials.gov Identifier: NCT00671346 JAMA. 2009; 302(19): 2119-2126

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据